Your safety is our first priority. Learn more about key medication details, possible side effects, warnings, and other important information about tirzepatide microdosing below.
Prescribing Information
Tirzepatide microdosing is a compounded, provider-determined lower-dose approach that may be prescribed when clinically appropriate. It is not a separately FDA-approved product or dosing regimen. Compounded tirzepatide is not FDA-approved as a finished drug product and is not the same as Zepbound® or Mounjaro®.
Black Box Warning
There is no FDA-approved prescribing label specific to compounded tirzepatide microdosing. However, FDA-approved tirzepatide products carry a boxed warning for the risk of thyroid C-cell tumors. Do not use tirzepatide if you or your family have a history of medullary thyroid carcinoma, or MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2, or MEN 2.
Common Side Effects
Common or possible side effects may include:
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Indigestion
- Decreased appetite
- Fatigue
- Burping or reflux
- Injection-site reactions
Important Safety Information
Do not use tirzepatide if you have a known allergy to tirzepatide or any ingredient in the medication, have a personal or family history of MTC, or have MEN 2.
Tell your provider if you have or have had pancreatitis, gallbladder disease, kidney disease, diabetes, diabetic retinopathy, severe stomach or digestion problems, depression, suicidal thoughts, or are pregnant, planning pregnancy, or breastfeeding.
Tirzepatide may increase the risk of pancreatitis, gallbladder problems, dehydration, kidney injury, severe gastrointestinal reactions, low blood sugar with certain diabetes medications, allergic reactions, and worsening diabetic retinopathy. Delayed stomach emptying can affect oral medications and may temporarily reduce the reliability of oral hormonal contraceptives after starting treatment or increasing the dose.
Compounded products may have different concentrations and syringe instructions. Confirm the dose in milligrams, milliliters, and syringe units before every injection. Do not use a dosing schedule that differs from your provider’s directions.
Seek urgent medical help for severe abdominal pain, swelling of the face or throat, trouble breathing, severe vomiting, fainting, symptoms of dehydration, or signs of an allergic reaction.
To report suspected adverse reactions, contact the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.
